Shandong Chengchuang Blue Sea Pharmaceutical Technology Co., LTD.

Letermovir Injection is a novel antiviral agent targeting the human cytomegalovirus (CMV) terminase complex. It inhibits CMV DNA cleavage and packaging to block viral replication, presenting a well-tolerated option for CMV prophylaxis in transplant recipients. It is administered via intravenous drip.

It is indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in eligible adult and paediatric allogeneic hematopoietic stem cell transplant recipients and high-risk kidney transplant patients.

Specification: 12ml:240mg

Packaging: Glass vial, 10 vials / box.

It is a first in class terminase inhibitor with a distinct mechanism from traditional CMV antivirals, showing lower risks of myelosuppression and nephrotoxicity. It delivers reliable CMV prophylaxis and helps reduce CMVrelated morbidity in transplant populations

The API is self-manufactured in-house. We maintain full control over impurities and production process under China GMP, with complete supporting data to facilitate your overseas registration.

We can supply qualified finished dosage forms, offer technology transfer, or discuss other flexible cooperation models. Please contact us for detailed documents, specifications and cooperation terms.